Gastrointestinal Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Gastrointestinal
| Protocol | NRG GI005 |
|---|---|
| Cancer Type: | Stage IIA Colon Cancer |
| Fast Facts |
Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
| Protocol | NRG GI008 |
|---|---|
| Cancer Type: | Colon Adjuvant |
| Fast Facts |
COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EA2186 |
|---|---|
| Cancer Type: | Metastatic Pancreatic |
| Fast Facts |
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
| Protocol | SWOG S2001 |
|---|---|
| Cancer Type: | Metastatic Pancreatic |
| Fast Facts |
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations.
| Protocol | Alliance A021806 |
|---|---|
| Cancer Type: | RESECTABLE PANCREATIC CANCER |
| Fast Facts |
A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S1922 |
|---|---|
| Cancer Type: | Small bowel Adenocarcinoma |
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EA2176 |
|---|---|
| Cancer Type: | treatment-naïve metastatic anal cancer |
| Fast Facts |
A Phase III Study of Immune checkpoint inhibition with chemotherapy in treatment-naïve metastatic anal cancer patients
| Protocol | EA2182 |
|---|---|
| Cancer Type: | Early Stage Anal Squamous Cell Carcinoma |
| Fast Facts |
A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EA2197 |
|---|---|
| Cancer Type: | Incidental Gallbladder Cancer |
| Fast Facts |
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN)- A Randomized Phase II/III Trial
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | NRG GI004 |
|---|---|
| Cancer Type: | Colorectal Cancer |
| Fast Facts |
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
| Protocol | SWOG S2107 |
|---|---|
| Cancer Type: | Metastatic Colorectal |
| Fast Facts |
Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EA2183 |
|---|---|
| Cancer Type: | Esophageal and Gastric Adenocarcinoma |
| Fast Facts |
A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | PDM 9846 |
|---|---|
| Cancer Type: | Tissue Procurement |
| Fast Facts |
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S0820 |
|---|---|
| Cancer Type: | Colorectal |
| Fast Facts |
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
| Protocol | WF 1806 |
|---|---|
| Cancer Type: | Cancer Control |
| Fast Facts |
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
| Protocol | Alliance A221805 |
|---|---|
| Cancer Type: | CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY |
DULOXETINE TO PREVENT OXALIPLATIN-INDUCED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TO PHASE III STUDY
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EA2185 |
|---|---|
| Cancer Type: | Pancreatic Cyst Surveillance |
| Fast Facts |
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
